SCHEMBL16118554

SCHEMBL16118554

CC[C@H](c1ccccc1)N1C(=O)COC1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 2/20 0.44
OPRM1 P35372 2/20 0.38
OPRD1 P41143 2/20 0.38
OPRK1 P41145 2/20 0.38
OPRL1 P41146 2/20 0.38
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
ALOX12 P18054 1/20 0.36
NR3C2 P08235 1/20 0.36
L3MBTL1 Q9Y468 2/20 0.35
ALDH1A1 P00352 1/20 0.35
TSHR P16473 1/20 0.35
SIGMAR1 Q99720 2/20 0.35
SLC6A2 P23975 1/20 0.35
SLC6A4 P31645 1/20 0.35
IDH1 O75874 2/20 0.34
LMNA P02545 1/20 0.34
ATM Q13315 1/20 0.34
PKM P14618 1/20 0.34
NPC1 O15118 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5164869 0.79 ALDH1A1 (0.46) HSD11B1KMT2AALOX12NR3C2ALDH1A1
SCHEMBL11082175 0.73 MEN1 (0.55) HSD11B1OPRM1OPRD1OPRK1OPRL1
SCHEMBL28286235 0.73 LMNA (0.41) HSD11B1OPRM1OPRD1OPRK1OPRL1
SCHEMBL12898667 0.71 ALDH1A1 (0.52) L3MBTL1ALDH1A1LMNA
SCHEMBL3625929 0.71 CHRM1 (0.34) KMT2AMEN1ALOX12ALDH1A1
SCHEMBL13878052 0.69 ALDH1A1 (0.43) HSD11B1OPRM1OPRD1OPRK1OPRL1
SCHEMBL22997584 0.67 HSD11B1 (0.51) HSD11B1KMT2AMEN1L3MBTL1LMNA
SCHEMBL22997081 0.67 HSD11B1 (0.51) HSD11B1KMT2AMEN1L3MBTL1LMNA
SCHEMBL2962625 0.66 OPRM1 (0.65) OPRM1OPRD1OPRK1OPRL1TSHR
SCHEMBL13923590 0.65 ALDH1A1 (0.40) HSD11B1OPRM1OPRD1OPRK1OPRL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160039842-A1 OXAZOLO[5,4-C]QUINOLIN-2-ONE COMPOUNDS AS BROMODOMAIN INHIBITORS EPIGENETIX, INC. 2016-02-11 US disclosed
US-20160039842-A1 OXAZOLO[5,4-C]QUINOLIN-2-ONE COMPOUNDS AS BROMODOMAIN INHIBITORS EPIGENETIX, INC. 2016-02-11 US disclosed
WO-2014152029-A2 OXAZOLO[5,4-C]QUINOLIN-2-ONE COMPOUNDS AS BROMODOMAIN INHIBITORS EPIGENETIX, INC. (US) 2014-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160039842-A1 OXAZOLO[5,4-C]QUINOLIN-2-ONE COMPOUNDS AS BROMODOMAIN INHIBITORS BRD4, BRD3, BRD2 HSD11B1 1538/4885OPRM1 2460/4885OPRD1 1809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.